HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

SU 12662

a metabolite of SU-11248
Also Known As:
N-desethyl sunitinib; SU-12662; SU12662
Networked: 15 relevant articles (0 outcomes, 5 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Arai, Yoichi: 2 articles (10/2018 - 02/2017)
2. Ito, Akihiro: 2 articles (10/2018 - 02/2017)
3. Kawasaki, Yoshihide: 2 articles (10/2018 - 02/2017)
4. Kikuchi, Masafumi: 2 articles (10/2018 - 02/2017)
5. Mano, Nariyasu: 2 articles (10/2018 - 02/2017)
6. Takasaki, Shinya: 2 articles (10/2018 - 02/2017)
7. Yamaguchi, Hiroaki: 2 articles (10/2018 - 02/2017)
8. Jaehde, U: 2 articles (01/2017 - 01/2011)
9. Kanefendt, F: 2 articles (01/2017 - 01/2011)
10. Kinzig, M: 2 articles (01/2017 - 01/2011)

Related Diseases

1. Renal Cell Carcinoma (Grawitz Tumor)
2. Neoplasms (Cancer)
10/01/2018 - "Several of the drug's metabolites, including its primary active metabolite SU12662, were detected in the tumor tissue over 13days. "
05/01/2015 - "One thousand two hundred and five plasma samples from 70 cancer patients were collected from three PK studies with sunitinib and SU12662. "
07/01/2015 - "This method can be used in routine clinical practice to monitor sunitinib and N-desethyl sunitinib drugs in the urine of cancer patients treated with once daily administration. "
05/01/2015 - "A semi-physiological PK model for sunitinib and SU12662 in cancer patients was presented including pre-systemic metabolism. "
07/01/2010 - "Tentative relationships were identified between (1) steady-state AUC of total drug (sunitinib + its active metabolite SU12662) and time to tumor progression (TTP), overall survival (OS), with AUC significantly associated with longer TTP and OS in patients with GIST and mRCC, and incidence, but not severity, of fatigue; (2) steady-state AUC of sunitinib and response probability, with AUC significantly associated with objective response in patients with mRCC and stable disease in patients with both mRCC and GIST (with no such correlations in patients with solid tumors); (3) dose and tumor size reductions; (4) total drug concentration and diastolic blood pressure (DBP), with a typical patient on sunitinib 50 mg QD (the recommended dose) predicted to experience a maximum DBP increase of 8 mmHg; and (5) cumulative AUC of total drug and absolute neutrophil count (ANC), with ANC reductions occurring predominantly after one treatment cycle. "
3. Colorectal Neoplasms (Colorectal Cancer)
4. Chronic Kidney Failure (Chronic Renal Failure)
5. Thrombocytopenia (Thrombopenia)

Related Drugs and Biologics

1. Sunitinib (Sutent)
2. Cytochrome P-450 CYP3A
3. Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
4. Adenosine Triphosphate (ATP)
5. Member 1 Subfamily B ATP Binding Cassette Transporter
6. Biomarkers (Surrogate Marker)
7. Proteins (Proteins, Gene)
8. thiamine triphosphorate (TTP)

Related Therapies and Procedures

1. Renal Dialysis (Hemodialysis)
2. Therapeutics